Abstract
B cells and autoantibodies have well-described pathological roles in systemic lupus erythematosus (SLE). Bradford et al.(1) now provide evidence that autoantibodies can also be protective by neutralizing type I interferons (IFNs) and restraining the activation of pathogenic B cells.